New cancer drug for dogs benefits human research, drug development
The drug, Verdinexor (KPT-335), works by preventing powerful tumor suppressing proteins from leaving the nucleus of cells, an exodus which allows cancer to grow unchecked. It’s the first new therapeutic option for dog lymphoma in more than two decades, potentially offering vets another alternative for treating the disease, which is the most common form of canine cancer…